Phathom Pharmaceuticals (PHAT) EBIAT: 2022-2025
Historic EBIAT for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$30.0 million.
- Phathom Pharmaceuticals' EBIAT rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.6 million, marking a year-over-year increase of 19.12%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.84% down from last year.
- Phathom Pharmaceuticals' EBIAT amounted to -$30.0 million in Q3 2025, which was up 60.46% from -$75.8 million recorded in Q2 2025.
- In the past 5 years, Phathom Pharmaceuticals' EBIAT registered a high of -$30.0 million during Q3 2025, and its lowest value of -$94.3 million during Q1 2025.
- Moreover, its 3-year median value for EBIAT was -$75.8 million (2025), whereas its average is -$66.9 million.
- Per our database at Business Quant, Phathom Pharmaceuticals' EBIAT crashed by 123.23% in 2024 and then soared by 64.98% in 2025.
- Phathom Pharmaceuticals' EBIAT (Quarterly) stood at -$55.0 million in 2022, then tumbled by 44.55% to -$79.6 million in 2023, then climbed by 6.43% to -$74.5 million in 2024, then soared by 64.98% to -$30.0 million in 2025.
- Its EBIAT was -$30.0 million in Q3 2025, compared to -$75.8 million in Q2 2025 and -$94.3 million in Q1 2025.